| 生物活性 |
AG-205 is a progesterone receptor membrane component 1 (PGRMC1) antagonist and ceramide galactosyltransferase (CGT) inhibitor with an IC50 of 50 μM against rat CGT, exhibiting anti-mitotic, anti-migratory, and anti-invasive activities, increasing the expression of genes encoding cholesterol biosynthesis pathway or steroidogenic enzymes, promoting apoptosis (Apoptosis)-mediated cell cycle regulation, and reducing the migration and invasion abilities of ovarian and breast cancer cells, and can be used for research related to renal cancer and breast cancer. |
体外研究 (In Vitro) |
AG-205 (10-40 μM; 24 h) 可显著提高 SMKT-R3 人肾癌细胞的存活率。 AG-205 (2-10 μM) 可特异性降低 SMKT-R3 人肾癌细胞中的硫苷脂水平,而对主要非鞘脂类无影响。 AG-205 (10 μM; 6 h) 可特异性抑制表达半乳糖脑苷脂合成酶的 CHO-CGT 和 CHO-Sulf 细胞中 CGT 依赖性半乳糖脂 (GalC、MGDG) 及硫脂的合成,同时促进 GlcC 的合成。 AG-205 (10 μM; 48 h) 可在 CHO-CGT 细胞中抑制 GalC 和 MGDG 的合成并促进 GlcC 的合成,该作用不依赖于 PGRMC1 或 PGRMC2 的表达。 AG-205 (50 μM; 30 min) 可显著抑制源自 CHO-CGT 细胞的 UDP-半乳糖:神经酰胺半乳糖基转移酶 (CGT) 的体外活性。 AG-205 (50 μM; 24 h pretreatment) 可消除孕酮对人颗粒/黄体细胞中 H2O2 诱导的细胞死亡的抗凋亡作用。 AG-205 (50 μM; 过夜) 可降低人颗粒/黄体细胞中 PGRMC1 的核定位水平,使大部分 PGRMC1 滞留于细胞质中。 AG-205 (50 μM; 过夜) 可提高人颗粒/黄体细胞中 HRK 蛋白的细胞质水平。 AG-205 (50 μM; 过夜) 会破坏人颗粒/黄体细胞中细胞色素 c 与线粒体的共定位,但不会改变细胞中细胞色素 c 的总水平。 AG-205 (50 μM; 过夜) 可增强人颗粒/黄体细胞中 PGRMC1 与 PGRMC2 的相互作用,表现为每个细胞的 PLA 点数增加 2.3 倍。 AG-205 (50 μM; 过夜) 可诱导人颗粒/黄体细胞中 Hrk mRNA 表达水平升高 6~8 倍,同时部分抗凋亡基因 mRNA 表达水平小幅升高 1.5~3 倍。 AG-205 (15 μM; 32 h) 可显著上调人子宫内膜 T-HESC 和 HEC-1A 细胞系中编码胆固醇生物合成酶、固醇调节因子 INSIG1 以及类固醇生成酶的基因的 mRNA 表达水平。 AG-205 (15 μM; 80 h) 可在人子宫内膜 T-HESC 和 HEC-1A 细胞系中上调 HSD17B7、MSMO1 和 INSIG1 的 mRNA 表达,且该过程不依赖于 PGRMC1 的表达。 AG-205 (15 μM; 80 h) 可在人子宫内膜 T-HESC 和 HEC-1A 细胞系中上调 HSD17B7、MSMO1 和 INSIG1 的 mRNA 表达,且该过程不依赖于全部 4 种 MAPR 家族成员 (PGRMC1、PGRMC2、NENF、CYB5D2) 的表达。 AG-205 (15 μM; 32 h) 不会改变人子宫内膜 T-HESC 和 HEC-1A 细胞系中 PGRMC1 的 mRNA 或蛋白表达水平,也不会改变该细胞系中 PGRMC1 的亚细胞定位。
Apoptosis Analysis
| Cell Line: |
human granulosa/luteal cells |
| Concentration: |
50 μM |
| Incubation Time: |
24 h (pretreatment) |
| Result: |
Eliminated progesterone's ability to attenuate H2O2-induced apoptosis, resulting in a dead cell/total cell ratio equivalent to H2O2 treatment alone. |
Immunofluorescence
| Cell Line: |
human granulosa/luteal cells |
| Concentration: |
50 μM |
| Incubation Time: |
overnight |
| Result: |
Reduced nuclear localization of PGRMC1; 31 ± 10% of cells showed nuclear PGRMC1 staining, compared to 67 ± 8% in controls. Prominently localized PGRMC1 to the cytoplasm in treated cells.\nIncreased levels of HRK protein in the cytoplasm of treated cells, visible as enhanced green fluorescence compared to controls.\nAltered the subcellular localization of cytochrome c, with a portion of cytochrome c no longer co-localizing with mitochondria (visible as diffuse green fluorescence in the cytoplasm) instead of being restricted to punctate mitochondrial foci. Left total cellular cytochrome c levels unchanged relative to controls. |
Western Blot Analysis
| Cell Line: |
human granulosa/luteal cells |
| Concentration: |
50 μM |
| Incubation Time: |
overnight |
| Result: |
Increased abundance of the ~27 kDa monomeric form of PGRMC1. Decreased abundance of the higher molecular weight forms ≥50 kDa (dimers/oligomers) of PGRMC1. |
Real Time qPCR
| Cell Line: |
human granulosa/luteal cells |
| Concentration: |
50 μM |
| Incubation Time: |
overnight |
| Result: |
Induced a 6 to 8 fold increase in Harakiri (Hrk) mRNA levels. Induced 1.5 to 3 fold increases in mRNA levels of Bag1, Bcl2A1, Birc3, Mcl1, and XIAP. Induced a small increase in Casp4 mRNA. |
Cell Viability Assay
| Cell Line: |
human endometrial T-HESC, HEC-1A |
| Concentration: |
5 μM, 15 μM, 30 μM, 45 μM |
| Incubation Time: |
24 h, 32 h, 48 h |
| Result: |
Had no effect on cell viability in either cell line for up to 48 h when used at 5 μM or 15 μM. |
Real Time qPCR
| Cell Line: |
human endometrial T-HESC, HEC-1A |
| Concentration: |
15 μM |
| Incubation Time: |
32 h |
| Result: |
Significantly upregulated mRNA expression of multiple enzymes involved in cholesterol biosynthesis, including ACAT2, AACS, HMGCS1, HMGCR, MVK, PMVK, MVD, IDI1, FDPS, FDFT1, SQLE, LSS, CYP51A1, TM7SF2, MSMO1, NSDHL, HSD17B7, EBP, SC5D, DHCR7, and DHCR24, in both cell lines. Upregulated mRNA expression of INSIG1 (a sterol-sensitive regulator) and steroidogenesis-related enzymes AKR1C1 and HSD17B14 in both cell lines. Confirmed significant upregulation of HSD17B7, MSMO1, and INSIG1 in both cell lines via qPCR. |
Real Time qPCR
| Cell Line: |
human endometrial T-HESC, HEC-1A (with prior siRNA-mediated knockdown of PGRMC1) |
| Concentration: |
15 μM |
| Incubation Time: |
32 h (following 48 h siRNA transfection) |
| Result: |
Induced a ~3 to 4-fold mean increase in HSD17B7, MSMO1, and INSIG1 mRNA expression in HEC-1A cells, and a ~4 to 6-fold mean increase in T-HESC cells. Maintained identical upregulation in cells transfected with PGRMC1-targeting siRNA or control siRNA. |
Real Time qPCR
| Cell Line: |
human endometrial T-HESC, HEC-1A (with prior siRNA-mediated knockdown of all four MAPR family members: PGRMC1, PGRMC2, NENF, CYB5D2) |
| Concentration: |
15 μM |
| Incubation Time: |
32 h (following 48 h siRNA transfection) |
| Result: |
Significantly upregulated mRNA expression of HSD17B7, MSMO1, and INSIG1 in both cell lines. Maintained upregulation at the same magnitude in cells transfected with the MAPR-targeting siRNA mixture as in control siRNA-transfected cells. |
|